文献速递神经肿瘤

36个月及以下儿童弥漫性内生性脑桥胶质瘤的特征:来自国际DIPG登记处报告

Characteristics of children ≤36 months of age with DIPG: A report from the international DIPG registry.
PubMed 文献 · Neuro Oncol · 2022-01-01

基于国际DIPG登记处(IDIPGR)1183例中筛选的40例≤36个月患儿,中位年龄29个月,中位总生存(OS)15个月,30%为长期生存者(OS≥24个月),92%长期生存者接受放疗;未治疗者中位OS 2个月,治疗者17个月。

要点

  • ≤36个月DIPG患儿中位OS为15个月,30%达长期生存(OS≥24个月)。
  • 长期生存者中92%接受了放疗,且症状持续时间更长(P = .018)。
  • 未治疗患儿中位OS为2个月,治疗患儿为17个月。

核心结论

  • ≤36个月DIPG患儿显示出更多长期生存,中位OS改善至15个月;92%的长期生存者接受了放疗。
  • 未治疗患儿中位OS为2个月,治疗患儿为17个月。
  • 长期生存者症状持续时间更长。
  • 被排除的患儿OS更低,反驳了≤36个月DIPG患儿因误诊而预后更好的假设。

研究设计与样本

  • 国际DIPG登记处(IDIPGR)纳入诊断时≤36个月且经中心影像确认的患儿,分析其表现、临床过程、影像、病理和分子结果。

主要发现

  • IDIPGR共1183例患者,40例符合条件,中位年龄29个月。
  • 中位OS为15个月;12例(30%)为长期生存者,3例(7.5%)为≥5年极长期生存者。
  • 8例未治疗患者中位OS为2个月;因中心影像审核或组织诊断被排除的患者中位OS为7个月。
  • 除1例外所有长期生存者均接受放疗;32例治疗患者1年、2年、3年和5年OS率分别为68.8%、31.2%、15.6%和12.5%。
  • 长期生存者症状持续时间更长(P = .018);无影像学特征可预测结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children ≤36 months with diffuse intrinsic pontine glioma (DIPG) have increased long-term survival (LTS, overall survival (OS) ≥24 months). Understanding distinguishing characteristics in this population is critical to improving outcomes. METHODS: Patients ≤36 months at diagnosis enrolled on the International DIPG Registry (IDIPGR) with central imaging confirmation were included. Presentation, clinical course, imaging, pathology and molecular findings were analyzed. RESULTS: Among 1183 patients in IDIPGR, 40 were eligible (median age: 29 months). Median OS was 15 months. Twelve patients (30%) were LTS, 3 (7.5%) very long-term survivors ≥5 years. Among 8 untreated patients, median OS was 2 months. Patients enrolled in the registry but excluded from our study by central radiology review or tissue diagnosis had median OS of 7 months. All but 1 LTS received radiation. Among 32 treated patients, 1-, 2-, 3-, and 5-year OS rates were 68.8%, 31.2%, 15.6% and 12.5%, respectively. LTS had longer duration of presenting symptoms (P = .018). No imaging features were predictive of outcome. Tissue and genomic data were available in 18 (45%) and 10 patients, respectively. Among 9 with known H3K27M status, 6 had a mutation. CONCLUSIONS: Children ≤36 months demonstrated significantly more LTS, with an improved median OS of 15 months; 92% of LTS received radiation. Median OS in untreated children was 2 months, compared to 17 months for treated children. LTS had longer duration of symptoms. Excluded patients demonstrated a lower OS, contradicting the hypothesis that children ≤36 months with DIPG show improved outcomes due to misdiagnosis.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Bartlett AL, Lane A, Chaney B, et al. Characteristics of children ≤36 months of age with DIPG: A report from the international DIPG registry. Neuro Oncol. 2022. PMID: 35552452. doi:10.1093/neuonc/noac123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。